Abstract：Objective To analyze the treatment outcomes of patients with primary sphenoid sinus malignancies. Methods Sixteen patients with primary sphenoid sinus malignancies admitted to our hospital from 2000 to 2013 were analyzed retrospectively. No patients were newly diagnosed with cervical lymph node metastasis. One patient had stage ⅣA disease, while fifteen had stage ⅣB disease. Eleven patients received surgery followed by radiotherapy, one surgery alone, three radiotherapy alone, and one chemotherapy alone.All surgeries were cytoreductive. The median dose of radiotherapy was 69.96 Gy (56.00-80.56 Gy). Results The 3-year local control (LC), distant metastasis-free survival (DMFS), disease-free survival (DFS), and disease-specific survival (DSS) rates were 67%, 69%, 44%, and 58%, respectively, in all patients, and 67%, 55%, 30%, and 41%, respectively, in patients treated with cytoreductive surgery followed by radiotherapy. All orbital contents and skull base were preserved. In all patients, the local recurrence, distant metastasis, and lymph node recurrence rates were 25%, 37%, and 6%, respectively. There were no independent predictors for the LC and DSS rates based on the prognostic analysis. Conclusions With the orbital contents and skull base preserved, the cytoreductive surgery followed by radiotherapy yields satisfactory outcomes and a low lymph node recurrence rate in the treatment of sphenoid sinus malignancies. The prophylactic irradiation of cervical lymph nodes is not recommended in clinical practice.
Liu Zhiping,Luo Jingwei,Xu Guozhen et al. Treatment of primary sphenoid sinus malignancies:an analysis of 16 patients[J]. Chinese Journal of Radiation Oncology, 2015, 24(6): 671-674.
[1] Franchi A,Miligi L,Palomba A,et al. Sinonasal carcinomas:recent advances in molecular and phenotypic characterization and their clinical implications[J].Crit Rev Oncol Hematol,2011,79(3):265-277.DOI:10.1016/j.critrevonc.2010.08.002. [2] Vedrine PO,Thariat J,Merrot O,et al. Primary cancer of the sphenoid sinus-a GETTEC study[J].Head Neck,2009,31(3):388-397.DOI:10.1002/hed.20966. [3] DeMonte F,Ginsberg LE,Clayman GL.Primary malignant tumors of the sphenoidal sinus[J].Neurosurgery,2000,46(5):1084-1091.DOI:10.1097/00006123－200005000－00012. [4] Esposito F,Kelly DF,Vinters HV,et al. Primary sphenoid sinus neoplasms:a report of four cases with common clinical presentation treated with transsphenoidal surgery and adjuvant therapies[J].J Neuro-oncol 2006,76(3):299-306.DOI:10.1007/s11060-005-7285-z. [5] Arnold A,Ziglinas P,Ochs K,et al. Therapy options and long-term results of sinonasal malignancies[J].Oral Oncol,2012,48(10):1031-1037.DOI:10.1016/j.oraloncology.2012.04.005. [6] Jansen EPM,Keus RB,Hilgers FJM,et al. Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma?[J].Int J Radiat Oncol Biol Phys,2000,48(1):27-35.DOI:10.1016/S0360-3016(00)00594-0. [7] Licitra L,Locati LD,Cavina R,et al. Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer[J].Ann Oncol,2003,14(3):367-372.DOI:10.1093/annonc/mdg113. [8] Katz TS,Mendenhall WM,Morris CG,et al. Malignant tumors of the nasal cavity and paranasal sinuses[J].Head Neck,2002,24(9):821-829.DOI:10.1002/hed.10143. [9] Guntinas-Lichius O,Kreppel MP,Stuetzer H,et al. Single modality and multimodality treatment of nasal and paranasal sinuses cancer:a single institution experience of 229 patients[J].Eur J Surg Oncol,2007,33(2):222-228.DOI:10.1016/j.ejso.2006.10.033. [10] Hoppe BS,Stegman LD,Zelefsky MJ,et al. Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting-the MSKCC experience[J].Int J Radiat Oncol Biol Phys,2007,67(3):691-702.DOI:10.1016/j.ijrobp.2006.09.023. [11] Hoppe BS,Nelson CJ,Gomez DR,et al. Unresectable carcinoma of the paranasal sinuses:outcomes and toxicities[J].Int J Radiat Oncol Biol Phys,2008,72(3):763-769.DOI:10.1016/j.ijrobp.2008.01.038.
2015, Vol. 24 
